This is the authors' abstract. We don't add key points for this paper.
Astrocytomas, the most common type of gliomas, and especially grade IV glioblastomas are "endowed" with strong proliferation and invasion potentials, high recurrence rate, and poor patients' prognosis. Aberrant signaling of AKT-mTOR (mammalian target of rapamycin) has been implicated in carcinogenesis. This paper is focused on the impact of deregulated AKT-mTOR signaling components in the clinical outcome and prognosis of human astrocytomas. Current therapeutic targeting of astrocytomas with AKT-mTOR inhibitors in preclinical and clinical stage is also discussed, including future perspectives regarding the management of these devastating tumors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
El-Habr et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: